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Many studies have implicated nuclear factor E2-related factor 2 (Nrf2) and nuclear factor-kB1 (Nfkb1) in inflammation and cancer.
However, the regulatory potential for crosstalk between these two important transcription factors in inflammation and carcinogenesis
has not been explored. To delineate conserved transcription factor-binding site signatures, we performed bioinformatic analyses on
the promoter regions of human and murine Nrf2 and Nfkb1. We performed multiple sequence alignment of Nrf2 and Nfkb1 genes
in five mammalian species – human, chimpanzee, dog, mouse and rat – to explore conserved biological features. We constructed a
canonical regulatory network for concerted modulation of Nrf2 and Nfkb1 involving several members of the mitogen-activated
protein kinase (MAPK) family and present a putative model for concerted modulation of Nrf2 and Nfkb1 in inflammation/
carcinogenesis. Our results reflect potential for putative crosstalk between Nrf2 and Nfkb1 modulated through the MAPK cascade
that may influence inflammation-associated etiopathogenesis of cancer. Taken together, the elucidation of potential relationships
between Nrf2 and Nfkb1 may help to better understand transcriptional regulation, as well as transcription factor networks, associated
with the etiopathogenesis of inflammation and cancer.
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The National Cancer Institute Inflammation and Cancer Think
Tank in Cancer Biology (NCI, 2008) has recognised that
epidemiological and clinical research corroborates an increased
risk of certain cancers in the setting of chronic inflammation.
Indeed, chronic inflammation, because of both infectious and non-
infectious etiologies, has been associated with an increased risk of
cancer development at a number of organ sites, with infectious
agents estimated to be responsible for the development of 18% of
all new cancer cases worldwide (Osburn et al, 2007). Infectious
agents linked to cancer include hepatitis B virus and liver cancer,
Helicobacter pylori and stomach cancer, and liver fluke infection
and cholangiocarcinoma (Osburn et al, 2007). In addition, a
number of inflammatory conditions without an infectious
aetiology result in a significantly increased cancer risk as
exemplified by chronic gastroesophageal reflux-induced oesopha-
geal cancer, proliferative inflammatory atrophy-induced prostate
cancer and chronic ulcerative colitis-associated colorectal cancer
(Schottenfeld and Beebe-Dimmer, 2006; Osburn et al, 2007).
Activation of inflammatory cells is accompanied by an increase in
the release of reactive oxygen species (ROS) at the site of
inflammation. Excess levels of ROS, due to chronic inflammation,
may contribute to carcinogenesis by reacting with DNA to form
oxidative DNA adducts possibly leading to mutagenesis and
impaired regulation of cellular growth (Osburn et al, 2007). Many
of the processes involved in inflammation (e.g., leukocyte
migration, dilatation of local vasculature with increased perme-
ability and blood flow and angiogenesis), when found in
association with tumours, are more likely to contribute to tumour
growth, progression and metastasis than to elicit an effective host
antitumour response (NCI, 2008). Recently, it has been shown
(Dougan and Dranoff, 2008) that signals downstream of the
receptor for advanced glycation end products can fuel chronic
inflammation, creating a microenvironment that is ideal for
tumour formation in a mouse model of skin cancer.
Nuclear factor E2-related factor 2 (Nrf2 or Nfe2l2) is indis-
pensable to cellular defense against many chemical insults of
endogenous and exogenous origin, which play major roles in the
etiopathogenesis of many cancers and inflammation-related
diseases such as inflammatory bowel disease and Parkinson’s
disease (Nair et al, 2007a). Under basal conditions, Nrf2 – a
member of the Cap-N-Collar family of transcription factors – is
sequestered in the cytoplasm by Keap1 resulting in enhanced
proteasomal degradation of Nrf2. In conditions of oxidative stress,
Nrf2 is released from Keap1 either by direct oxidative modification
of Keap1 or after phosphorylation by redox-sensitive protein
kinases, translocates to the nucleus and, in combination with other
transcription factors, activates transcription of genes containing an
antioxidant response element (ARE) in their promoter regions
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sresulting in a cytoprotective adaptive response. This adaptive
response is characterised by upregulation of a battery of
antioxidative enzymes and decreased sensitivity to oxidative
damage and cytotoxicity. These antioxidative enzymes have also
been shown to attenuate inflammatory damage and neutralise ROS
implicated in inflammatory signalling pathways. We have also
reported (Khor et al, 2006) that Nrf2 could play an important role
in protecting intestinal integrity, through the regulation of
pro-inflammatory cytokines and induction of phase II detoxifying
enzymes. Besides, we have demonstrated (Yuan et al, 2006) that
mitogen-activated protein kinase (MAPK) pathways such as
extracellular signal-regulated kinase (ERK) and c-jun N-terminal
kinase (JNK) signalling pathways played important and positive
roles in chemopreventive agent butylated hydroxyanisole-induced
and Nrf2-dependent regulation of ARE-mediated gene expression,
as well as the nuclear translocation of Nrf2 in HepG2 cells. We
have observed earlier (Yu et al, 2000) that the activation of MAPK
pathways induces ARE-mediated gene expression through a Nrf2-
dependent mechanism. In addition, we have also shown (Shen
et al, 2004) that different segments of the Nrf2 transactivation
domain have different transactivation potentials and that different
MAPKs have differential effects on Nrf2 transcriptional activity,
with ERK and JNK pathways playing an unequivocal role in the
positive regulation of Nrf2 transactivation domain activity (Shen
et al, 2004; Nair et al, 2007a).
Importantly, recent mouse studies provide strong and direct
genetic evidence that the classical IKK-b (inhibitor of nuclear
factor-kB (NF-kB) kinase-b)-dependent NF-kB activation pathway,
which was proposed several years ago to be the molecular link
between inflammation and carcinogenesis, is a crucial mediator of
tumour promotion (Karin and Greten, 2005). Indeed, several pro-
inflammatory cytokines and chemokines – such as tumour
necrosis factor (TNF), IL-1, IL-6 and CXC-chemokine ligand 8
(CXCL8; also known as IL-8), all of which are encoded by the
target genes of the IKK-b-dependent NF-kB activation pathway –
are associated with tumour development and progression in
humans and mice. It has, thus, been hypothesised that activation of
NF-kB by the classical IKK-dependent pathway is a crucial
mediator of inflammation-induced tumour growth and progres-
sion, as well as an important modulator of tumour surveillance and
rejection (Karin and Greten, 2005). We have also demonstrated
(Xu et al, 2005) that the suppression of NF-kB and NF-kB-
regulated gene expression (VEGF, cyclin D1 and Bcl-XL) by
chemopreventive isothiocyanates sulphoraphane and phenethyl
isothiocyanate (PEITC) is mainly mediated through the inhibition
of IKK phosphorylation, particularly IKK-b, and the inhibition of
IkB-a phosphorylation and degradation, as well as the decrease of
nuclear translocation of p65 in human prostate cancer PC-3 cells.
Recently, it has been observed (Murakami et al, 2007) that PEITC
suppresses receptor activator of NF-kB ligand-induced osteoclasto-
genesis by blocking the activation of ERK1/2 and p38 MAPK in
RAW264.7 macrophages. Besides, HL60 cells treated with fisetin
presented high expression of NF-kB, activation of p38 MAPK and
an increase of phosphoprotein levels (de Sousa et al, 2007).
Pro-inflammatory biomarkers such as IL-1b, IL-6, TNF-a,
inducible nitric oxide synthase and cycloxygenase-2, which are
all effector genes regulated by the NF-kB pathway, have been noted
(Li et al, 2008) to exhibit greater induction in Nrf2-deficient mice
as compared with wild-type mice, indicating that ablation of Nrf2
seems to accelerate NF-kB-mediated pro-inflammatory reactions.
Besides, it has been shown recently (Liu et al, 2008) that NF-kB
competes with Nrf2 for binding to transcriptional coactivator
CREB-binding protein and also promotes the recruitment of the
corepressor histone deacetylase 3 to MafK leading to local histone
hypoacetylation, thus, serving as a negative regulator of Nrf2–ARE
signalling. Further, as constitutively active NF-kB occurs in
many inflammatory and tumour tissues (Liu et al, 2008), and as
Nrf2 is implicated in the etiopathogenesis of many cancers and
inflammation-associated conditions (Nair et al, 2007a), we elected
to select these two important transcriptional regulators in this
study to explore the potential for putative crosstalk between Nrf2
and NF-kB signalling pathways in inflammation/injury and
carcinogenesis. We performed in silico bioinformatic analyses to
delineate conserved transcription factor-binding sites (TFBSs) or
regulatory motifs in the promoter regions of human and murine
Nrf2 and Nfkb1, as well as coregulated genes. We performed
multiple sequence alignment of Nrf2 and Nfkb1 genes in five
mammalian species and studied conserved biological features. We
also looked at microarray data from public repositories such as
Oncomine (Rhodes et al, 2005), Gene Expression Omnibus (GEO),
Public Expression Profiling Resource (PEPR), as well as data sets
from the Kong Laboratory, to dissect the role(s) of key regulatory
genes in these selected inflammation/cancer signatures and
constructed a regulatory network for concerted modulation of
Nrf2 and Nfkb1 involving several members of the MAPK family.
Our in silico analyses show that concerted modulation of Nrf2 and
NF-kB signalling pathways, and putative crosstalk involving
multiple members of the MAPK family, may be potential molecular
events governing inflammation and carcinogenesis.
MATERIALS AND METHODS
Identification of microarray data sets bearing
inflammation/injury or cancer signatures
We perused several microarray data sets from public repositories
such as Oncomine, GEO, PEPR, as well as data sets from the Kong
Laboratory (Nair et al, 2006, 2007b, 2008). We selected 13 data sets
that presented distinct signatures of inflammation or injury or
carcinogenesis. Specifically, these studies reflected data on prostate
cancer, spinal trauma, inflammatory response to injury and genes
modulated by chemopreventive agents/toxicants in Nrf2-deficient
animal models. These studies encompassed three mammalian
species – human, mouse and rat – and exhibited modulation of
both Nrf2 (Nfe2l2) and Nfkb1 genes as well as coregulated genes.
Promoter analyses for transcription factor-binding sites
The promoter analyses were performed in the Cai Laboratory
using Genomatix MatInspector (Quandt et al, 1995; Cartharius
et al, 2005). Briefly, human promoter sequences of NFE2L2 and
NFKB1, or corresponding murine promoter sequences, were
retrieved from Gene2Promoter (Genomatix). Comparative
promoter analyses were then performed by input of these
sequences in FASTA format into MatInspector using optimised
default matrix similarity thresholds. The similar and/or function-
ally related TFBSs were grouped into ‘matrix families,’
and graphical representations of common TFBS were generated.
The ‘V$’ prefixes to the individual matrices are representative
of the Vertebrate MatInspector matrix library. Similarly, we
also elucidated common TFBS among the three topmost
conserved human regulatory sequences after multiple alignment
(as described below) of NRF2 and NFKB1 sequences.
Multiple species alignment of Nrf2 (Nfe2l2) and Nfkb1
sequences
Non-coding sequences of Nfe2l2 and Nfkb1 genes in five
mammalian species – human, chimpanzee, dog, mouse and
rat – were retrieved using the Non-Coding Sequence Retrieval
System (NCSRS) for comparative genomic analysis of gene
regulatory elements that has been previously developed and
published (Doh et al, 2007) by the Cai Laboratory, and is readily
available at http://cell.rutgers.edu/ncsrs/. Multiple sequence align-
ment was performed by submitting the non-coding sequences to
MLAGAN (Multi-LAGAN, Multi-Limited Area Global Alignment of
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VISTA visualisation tool. The MLAGAN alignments were, thus,
visualised using VISTA by projecting them to pairwise alignments
with respect to one reference sequence (human) as baseline. The
common TFBSs between Nfe2l2 and Nfkb1 between the top
biological features that were conserved in multiple species were
then determined using Genomatix MatInspector as described
earlier in Materials and Methods under Promoter Analyses for
TFBS.
Construction and validation of canonical first-generation
regulatory network involving Nrf2 (Nfe2l2) and Nfkb1
A putative regulatory network for Nrf2 (Nfe2l2) and Nfkb1,
representing 59 nodes and 253 potential interactions, was
constructed using Cytoscape 2.5.2 software (Shannon et al,
2003). Further, we validated our network using PubGene (Jenssen
et al, 2001), a literature network where connections are strong
indicators of biological interaction. Additional validation was
achieved by the generation of a biological network with these gene
identifiers through the use of Ingenuity Pathways Analysis
(Ingenuity Systems
s; www.ingenuity.com). For this purpose, a
data set containing gene identifiers was uploaded into the
application. Each gene identifier was mapped to its corresponding
gene object in the Ingenuity Pathways Knowledge Base. These
genes, called focus genes, were overlaid onto a global molecular
network developed from information contained in the Ingenuity
Pathways Knowledge Base. Networks of these focus genes were
then algorithmically generated based on their connectivity. In
addition, we used dChip application (Li and Hung Wong, 2001; Li
and Wong, 2001) to assess differential expression of MAPKs in
cancer vs developmental or non-cancerous tissue/cell lines. Briefly,
the CEL files created from each data set were first imported into
dChip software for further data characterisation. A gene informa-
tion file with current annotations and functional gene ontology
was generated and the Affymetrix Chip Description File (CDF) was
specified. The data were then normalised in dChip, and the
expression value for each gene was determined by calculating the
average of differences in intensity (perfect match intensity minus
mismatch intensity) between its probe pairs. Finally, clustering
and enrichment analysis was performed.
A putative model for Nrf2–Nfkb1 interactions in
inflammation and carcinogenesis
A pictorial model for Nrf2–Nfkb1 interactions was generated
using Pathway Builder Tool 2.0 available from Protein Lounge, San
Diego, CA, USA.
RESULTS
Identification of microarray data sets bearing
inflammation/injury or cancer signatures
To investigate distinct signatures of inflammation/injury or
carcinogenesis, we perused several microarray data sets from
public repositories such as Oncomine, GEO, PEPR, as well as
microarray data sets from the Kong Laboratory. As summarised in
Table 1, we selected 13 data sets that presented distinct signatures
of inflammation/injury or carcinogenesis. Specifically, these
studies reflected data on prostate cancer, spinal trauma, inflam-
matory response to injury and genes modulated by chemopreven-
tive agents/toxicants in Nrf2-deficient animal models. These
studies encompassed three mammalian species – human, mouse
and rat – and exhibited modulation of both Nrf2 (or Nrf2-
dependent) and Nfkb1 genes as well as coregulated genes. In other
words, all these studies presented modulation of both Nrf2
(Nfe2l2) and Nfkb1 genes in concert, except for the studies with
Nrf2-deficient animal models where Nrf2-dependent genes were
elucidated. Interestingly, these data sets exhibited modulation of
several key members of the MAPK family as well as cofactors of
Nrf2 and Nfkb1. This literature pre-screen encouraged us to
investigate further the regulatory potential for concerted modula-
tion of Nrf2- and Nfkb1-mediated gene expression in inflammation
and carcinogenesis using an in silico bioinformatic approach.
Comparative promoter analyses of Nrf2 (Nfe2l2) and Nfkb1
for conserved transcription factor-binding sites
To identify conserved TFBS signatures, we performed comparative
analyses of Nrf2 and Nfkb1 murine promoter sequences
(Figure 1A) using Genomatix MatInspector (Quandt et al, 1995;
Cartharius et al, 2005) as described in Materials and Methods.
We also studied NRF2 and NFKB1 human promoter sequences
(Figure 1B) similarly. Table 2 includes, as indicated, an
alphabetical listing of the conserved vertebrate (V$) matrix
families between these two transcription factors. The major human
matrix families included activator protein 4 and related proteins,
Ccaat/enhancer-binding protein, Camp-responsive element-bind-
ing proteins, E2F-myc activator/cell cycle regulator, E-box-binding
factors, basic and erythroid krueppel-like factors, fork head
domain factors, Myc-associated zinc fingers, nuclear receptor
subfamily 2 factors, p53 tumour suppressor, RXR heterodimer-
binding sites, SOX/SRY-sex/testis-determining and related HMG
box factors, signal transducer and activator of transcription
(STAT), X-box-binding factors, Zinc-binding protein factors and
two-handed zinc finger homoeodomain transcription factors,
Table 1 Microarray data sets bearing inflammation/injury or cancer signatures
Species Tissue Study Data source Descriptor Affymetrix platform
Human Prostate Lapointe Oncomine Prostate cancer Non-Affymetrix
Human Prostate Luo Oncomine Prostate cancer and benign prostatic hyperplasia Non-Affymetrix
Mouse Lung Kleeberger GEO Hyperoxic lung injury MG U74Av2
Mouse Lung Papaiahgari GEO Lung injury and inflammatory response MG 430A 2.0
Mouse Spleen and liver Li GEO Autoimmune disease and Nrf2 MG U74Av2
Mouse Type II cells Machireddy GEO Nrf2 wild-type and knockout cells MG 430 2.0
Mouse Prostate Nair 1 Kong Laboratory EGCG+SFN combination treatment MG 430 2.0
Mouse Small intestine and liver Nair 2 Kong Laboratory BHA treatment MG 430 2.0
Mouse Small intestine and liver Nair 3 Kong Laboratory Induction of ER stress with TM MG 430 2.0
Rat Spinal cord Faden 1 PEPR Supraspinal tracts RG_U34A
Rat Spinal cord Faden 2 PEPR Trauma above T9 RG_U34A
Rat Spinal cord Faden 3 PEPR Trauma below T9 RG_U34A
Rat Spinal cord Faden 4 PEPR Trauma T9 RG_U34A
BHA¼butylated hydroxyanisole; EGCG¼epigallocatechin-3-gallate; ER¼endoplasmic reticulum; SFN¼sulphoraphane; TM¼tunicamycin. All Nair data sets are from the Kong
Laboratory as discussed in Materials and Methods; all Faden data sets are as defined by descriptors detailed above at the PEPR resource; all other data sets are as defined by
descriptors detailed above at the Oncomine or GEO resources.
Nrf2- and Nfkb1-mediated gene expression
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included AHR-arnt heterodimers and AHR-related factors,
activator protein 2, activator protein 4 and related proteins,
E2F-myc activator/cell cycle regulator, E-box-binding factors,
basic and erythroid krueppel-like factors, farnesoid X-activated
receptor response elements, heat-shock factors, Ikaros zinc finger
family, Myc-associated zinc fingers, NF-kB/c-rel, nuclear receptor
subfamily 2 factors, nuclear respiratory factor 1, p53 tumour
suppressor, pleomorphic adenoma gene, RXR heterodimer-bind-
ing sites, SOX/SRY-sex/testis-determining and related HMG box
factors, serum response element-binding factor, Tata-binding
protein factor, zinc-binding protein factors, among others.
Indeed, as evident from Table 2, several matrix families were
conserved between Nrf2 and Nfkb1 in both human and murine
promoters.
Multiple species alignment of Nrf2 (Nfe2l2) and Nfkb1
sequences
With the objective of investigating conserved biological features
across different mammalian species, we performed multiple
species alignment of Nrf2 (Nfe2l2) and Nfkb1 sequences as
described in Materials and Methods. We used NCSRS for
comparative genomic analysis of gene regulatory elements that
has been previously developed and published (Doh et al, 2007),
and is readily available at http://cell.rutgers.edu/ncsrs/ and
retrieved non-coding sequences of Nfe2l2 and Nfkb1 genes in five
mammalian species – human, chimpanzee, dog, mouse and rat. As
shown in Figures 2A and B, we performed multiple sequence
alignment using MLAGAN (Brudno et al, 2003) for Nfe2l2 and
Nfkb1 genes, respectively, with respect to one reference sequence
(human) as baseline. The phylogenetic tree for Nfe2l2 and Nfkb1 in
the five species under consideration was constructed (Figure 2C).
The conserved biological features across species for each of Nfe2l2
and Nfkb1 genes were perused, and the top five features for Nfe2l2
and the top three features for Nfkb1, as numbered in Figures 2A
and B, are listed in Tables 3A and B, respectively. Sequence 4 for
Nfe2l2 and sequence 1 for Nfkb1 exhibited the highest degree of
conservation across species at 98.86 and 86.58%, respectively. In
addition, the top three conserved sequences in the human
sequences of both these genes (sequences 4, 3 and 2 for Nfe2l2
in that order and sequences 1, 2 and 3 for Nfkb1 in that order) as
evident from Tables 3A and B were submitted to Genomatix
MatInspector. The common TFBSs between Nfe2l2 and Nfkb1
between these biological features that were conserved in multiple
species were then determined (Figure 2D) and tabulated along with
the other TFBS results for comparative promoter analyses in
Table 2 discussed earlier.
Construction and validation of a canonical first-generation
regulatory network involving Nrf2 (Nfe2l2) and Nfkb1
To construct a canonical first-generation biological network for
Nrf2–Nfkb1 interactions, we streamlined our study to five data
sets summarised in Table 4, which were representative of the most
distinct inflammation/injury and cancer signatures from the 13
data sets perused earlier. We obtained gene expression values for
59 genes, as shown in Table 4, including Nrf2 (Nfe2l2), Nfkb1,
several cofactors and many members of the MAPK family from
these data sets. As shown in Figure 3A, we constructed a putative
first-generation regulatory network for Nrf2 (Nfe2l2) and Nfkb1,
representing 59 nodes and 253 potential interactions using
Cytoscape 2.5.2 software (Shannon et al, 2003). Further, we
validated our network by submitting 20 representative genes from
Table 4 to PubGene (Jenssen et al, 2001), a literature network
where connections are strong indicators of biological interaction,
and retrieved biological networks in human (Figure 3B) and mouse
(Figure 3C), thus delineating gene signatures that validated the
putative biological role(s) of the genes elucidated in this in silico
study that served as the source and target nodes in our regulatory
network. We further validated our network by querying Ingenuity
Pathways Analysis (Ingenuity Systems; www.ingenuity.com)
application with the 59 gene identifiers forming the basis of our
network and obtained a biological network (Figure 3D) with a high
degree of functional crosstalk based on the Ingenuity Knowledge
Base reiterating the potential for crosstalk between multiple
members of the MAPK family that might modulate the Nrf2–
Nfkb1 interactions as indicated in our canonical network
(Figure 3A). Furthermore, we used dChip application (Li and
Hung Wong, 2001; Li and Wong, 2001) to assess the differential
expression of MAPKs in cancerous vs developmental or non-
cancerous tissue/cell lines by using several unrelated microarray
data sets from the GEO resource at the NCBI including
GSM116104–116106: bronchial smooth muscle cells; GSM133871-
133873: retinal pigment epithelial cell line; GSM156176–156178:
skeletal muscle; GSM187371–187373: untreated LNCaP cells;
GSM211446–211448: normal adrenal gland; GSM286756–286758:
untreated MCF7 cells; GSM74875–74880: benign prostate tissue;
A
B
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Figure 1 (A) A conserved TFBS between mouse Nfe2l2 and Nfkb1. Vertebrate (V$) matrix families conserved between murine Nfe2l2 and Nfkb1
promoter regions were identified using Genomatix MatInspector. (B) A conserved TFBS between human NFE2L2 and NFKB1. Vertebrate (V$) matrix
families conserved between human NFE2L2 and NFKB1 promoter regions were identified using Genomatix MatInspector.
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sTable 2 Human and murine matrix families conserved between Nrf2 and Nfkb1
Matrix family
(Human NRF2
vs NFKB1)
Matrix family
(Murine Nrf2
vs Nfkb1)
Matrix family
conserved after
multiple species
alignment
(NRF2 vs NFKB1) Family information
– V$AHRR – AHR-arnt heterodimers and AHR-related factors
– – V$AIRE Autoimmune regulatory element-binding factor
– – V$AP1R MAF- and AP1-related factors
– V$AP2F – Activator protein 2
V$AP4R V$AP4R – Activator protein 4 and related proteins
– – V$ATBF AT-binding transcription factor
– V$BCL6 V$BCL6 POZ domain zinc finger expressed in B-cells
– – V$BRAC Brachyury gene, mesoderm developmental factor
– – V$BRNF Brn POU domain factors
– – V$CAAT CCAAT-binding factors
– – V$CART Cart-1 (cartilage homoeoprotein 1)
– – V$CDXF Vertebrate caudal related homoeodomain protein
V$CEBP – – Ccaat/enhancer-binding protein
V$CHRF – V$CHRF Cell cycle regulators: cell cycle homology element
– – V$CIZF CAS-interating zinc finger protein
– – V$CLOX CLOX and CLOX homology (CDP) factors
– – V$COMP Factors that cooperate with myogenic proteins
V$CREB – V$CREB Camp-responsive element-binding proteins
– V$CTCF – CTCF and BORIS gene family, transcriptional regulators
with 11 highly conserved zinc finger domains
V$E2FF V$E2FF – E2F-myc activator/cell cycle regulator
– V$E4FF – Ubiquitous GLI-krueppel-like zinc finger involved in cell cycle regulation
V$EBOX V$EBOX – E-box-binding factors
– V$EGRF – EGR/nerve growth factor-induced protein C and related factors
V$EKLF V$EKLF V$EKLF Basic and erythroid krueppel-like factors
– V$EREF – Estrogen response elements
V$ETSF V$ETSF – Human and murine ETS1 factors
– – V$EVI1 EVI1 myeloid-transforming protein
V$FKHD – V$FKHD Fork head domain factors
– V$FXRE – Farnesoid X-activated receptor response elements
V$GATA V$GATA V$GATA GATA-binding factors
V$GFI1 – V$GFI1 Growth factor independence transcriptional repressor
– – V$GREF Glucocorticoid responsive and related elements
– – V$GRHL Grainyhead-like transcription factors
V$HAND – – bHLH transcription factor dimer of HAND2 and E12
– V$HEAT V$HEAT Heat-shock factors
– V$HESF – Vertebrate homologues of enhancer of split complex
– – V$HNF1 Hepatic nuclear factor 1
– – V$HNF6 Onecut homoeodomain factor HNF6
– – V$HOMF Homoeodomain transcription factors
– – V$HOXC HOX–PBX complexes
V$HOXF V$HOXF V$HOXF Factors with moderate activity to homoeodomain consensus sequence
– V$IKRS – Ikaros zinc finger family
– – V$IRFF Interferon regulatory factors
V$LEFF – V$LEFF LEF1/TCF, involved in the Wnt signal transduction pathway
– – V$LHXF Lim homoeodomain factors
V$MAZF V$MAZF – Myc-associated zinc fingers
– – V$MEF2 MEF2, myocyte-specific enhancer-binding factor
V$MYBL – – Cellular and viral myb-like transcriptional regulators
V$MYOD V$MYOD – Myoblast-determining factors
– – V$MYT1 MYT1 C2HC zinc finger protein
– V$MZF1 – Myeloid zinc finger 1 factors
V$NEUR – V$NEUR NeuroD, b2, HLH domain
– – V$NF1F Nuclear factor 1
– – V$NFAT Nuclear factor of activated T cells
– V$NFKB – Nuclear factor k B/c-rel
– – V$NKX6 NK6 homoeobox transcription factors
– – V$NKXH NKX homoeodomain factors
V$NR2F V$NR2F V$NR2F Nuclear receptor subfamily 2 factors
– V$NRF1 – Nuclear respiratory factor 1
– – V$OCT1 Octamer-binding protein
– – V$OCTP OCT1-binding factor (POU-specific domain)
V$P53F V$P53F – p53 tumour suppressor
– – V$PARF PAR/bZIP family
V$PAX5 – – PAX-5 B cell-specific activator protein
– V$PAX6 V$PAX6 PAX-4/PAX-6 paired domain-binding sites
– – V$PBXC PBX1–MEIS1 complexes
– – V$PDX1 Pancreatic and intestinal homoeodomain transcription factor
– – V$PERO Peroxisome proliferator-activated receptor
– – V$PIT1 GHF-1 pituitary-specific pou domain transcription factor
– V$PLAG – Pleomorphic adenoma gene
V$PLZF – V$PLZF C2H2 zinc finger protein PLZF
– – V$PRDF Positive regulatory domain I-binding factor
– – V$PTF1 Pancreas transcription factor 1, heterotrimeric transcription factor
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sTable 2 (Continued)
Matrix family
(Human NRF2
vs NFKB1)
Matrix family
(Murine Nrf2
vs Nfkb1)
Matrix family
conserved after
multiple species
alignment
(NRF2 vs NFKB1) Family information
– – V$RBIT Regulator of B-cell IgH transcription
– – V$RUSH SWI/SNF-related nucleophosphoproteins with a RING finger DNA-binding motif
V$RXRF V$RXRF V$RXRF RXR heterodimer-binding sites
– – V$SATB Special AT-rich sequence-binding protein
V$SF1F – V$SF1F Vertebrate steroidogenic factor
– V$SMAD – Vertebrate SMAD family of transcription factors
– – V$SNAP snRNA-activating protein complex
V$SORY V$SORY V$SORY SOX/SRY-sex/testis-determining and related HMG box factors
V$SP1F V$SP1F V$SP1F GC-Box factors SP1/GC
– V$SRFF V$SRFF Serum response element-binding factor
V$STAT – V$STAT Signal transducer and activator of transcription
– – V$TALE TALE homoeodomain class-recognising TG motifs
– V$TBPF V$TBPF Tata-binding protein factor
– V$WHNF – Winged helix-binding sites
V$XBBF – – X-box-binding factors
V$ZBPF V$ZBPF – Zinc-binding protein factors
V$ZF35 – – Zinc finger protein ZNF35
V$ZFHX – V$ZFHX Two-handed zinc finger homoeodomain transcription factors
1
3
5
4
Nfe2I2
Nfe2I2
Chimp
Dog
Mouse
Rat
Chimp
Dog
Mouse
Rat
Chimp
Dog
Mouse
Rat
Chimp
Dog
Mouse
Rat
Chimp
Dog
Mouse
Rat
Chimp
Dog
Mouse
Rat
Chimp
Dog
Mouse
Rat
0k 3k 6k 9k 12k 15k 18k 21k 25k 28k 31k 34k 37k 40k 43k 46k 49k
0k 10k 20k 30k 40k 50k 60k 70k
Nfkb1
Nfkb1
80k 90k 100k
100k 110k 120k 130k 140k 150k 160k 170k 180k
200k 210k 220k 230k 240k 250k 260k 270k 280k
190k 200k
100k 103k 106k 109k 112k 115k 118k 121k
150k
NFkb1
Nrf2
153k
100 bp
V$AIRE
V$CIZF
V$GRHL
V$MEF2
V$PARF
V$RUSH
V$TBPF
V$AP1R
V$CLOX
V$HEAT
V$MYT1
V$PAX4
V$RXRF
V$ZFHX
V$ATBF
V$COMP
V$HNF1
V$NEUR
V$PBXC
V$SATB
V$BCL6
V$CREB
V$HNF6
V$NF1F
V$PDX1
V$SF1F
V$BRAC
V$EKLF
V$HOMF
V$NFAT
V$PERO
V$SNAP
V$BRNF
V$EVI1
V$HOXC
V$NKX6
V$PIT1
V$SORY
V$CAAT
V$FKHD
V$HOXF
V$NKXH
V$PLZF
V$SP1F
V$CART
V$GATA
V$IRFF
V$NR2F
V$PRDF
V$SRFF
V$CDXF
V$GFI1
V$LEFF
V$OCT1
V$PTF1
V$STAT
V$CHRF
V$GREF
V$LHXF
V$OCTP
V$RBIT
V$TALE
1 1821
156k 159k 162k 165k 168k 171k
125k 128k 131k 134k 137k 140k 143k 146k 149k
50k 53k 56k 59k 62k 65k 68k 71k 75k 78k 81k 84k 87k 90k 93k 96k 99k
Nfe2I2
Nfe2I2
2
3
12
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
100%
50%
Chimp
Human
Dog
Mouse
Rat
A
D
C
B
Figure 2 Multiple species alignment. Non-coding sequences of Nfe2l2 and Nfkb1 genes in five mammalian species – human, chimpanzee, dog, mouse and
rat – were retrieved using the Non-Coding Sequence Retrieval System (NCSRS) for comparative genomic analysis of gene regulatory elements. Multiple
sequence alignment was performed by submitting the non-coding sequences to MLAGAN and visualised by projecting them to pairwise alignments with
respect to one reference sequence (human) as baseline. Pink regions, conserved non-coding sequences (CNS); dark blue regions, exons. The numbers
indicate CNS that were identified across species. (A) Multiple species alignment for Nfe2l2; (B) multiple species alignment for Nfkb1; (C) phylogenetic tree
for Nfe2l2 and Nfkb1; (D) a conserved TFBS between NFE2L2 and NFKB1 among top matching human sequences.
Nrf2- and Nfkb1-mediated gene expression
S Nair et al
2075
British Journal of Cancer (2008) 99(12), 2070–2082 & 2008 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sGSM74881–74887: clinically localised primary prostate cancer;
and GSM74888–74893: metastatic prostate cancer. Results from
this analysis (Figure 3E) show the differential expression of several
MAPKs in cancer vs non-cancerous tissue.
A putative model for Nrf2–Nfkb1 interactions in
inflammation and carcinogenesis
On the basis of the extensive experience (Yu et al, 2000; Li et al,
2005, 2006; Yuan et al, 2006; Nair et al, 2007a; Prawan et al, 2008)
of the Kong Laboratory with Nrf2–Keap1 pathway and role(s) of
MAPK/dietary chemopreventives/toxicants, our many microarray
studies (Shen et al, 2005, 2006; Keum et al, 2006; Nair et al, 2006,
2007b, 2008; Hu et al, 2006a,b; Barve et al, 2008) in Nrf2-deficient
mice, our studies (Jeong et al, 2004; Xu et al, 2005) on NF-kB
pathway and chemopreventive agents, and the gene signatures
elicited in inflammation and carcinogenesis in this in silico study
using our data as well as publicly available data from other
research groups as indicated earlier, we generated a pictorial
model (Figure 4) for Nrf2–Nfkb1 interactions using Pathway
Builder Tool 2.0. available from Protein Lounge, San Diego, CA. In
essence, chemical signals generated by dietary chemopreventive
agents or toxicants, or inflammatory signals, may cause Nrf2
nuclear translocation that sets in motion a dynamic machinery of
coactivators and corepressors that may form a multi-molecular
complex with Nrf2 to modulate transcriptional response through
Table 3 (A) Multiple species alignment for Nfe2l2. (B) Multiple species alignment for Nfkb1
Nfe2l2 CNS start CNS end % id Location Length Score Chr Strand Start End
(A)
1 84.2 200.50 87.57
Human 4424 4568 – Intergenic 144 2   177796698 177796842
Chimpanzee 1559 12467 98.4 Intergenic 2b   182248910 182259818
Dog 4037 4426 78.9 Intergenic 389 36   24010936 24011325
Mouse 3993 4131 79.6 Intergenic 138 2   75470119 75470257
Rat 4002 4133 80.0 Intergenic 131 3   58360804 58360935
2 79.9 801.25 93.25
Human 46618 47576 – Intronic 958 2   177838892 177839850
Chimpanzee 16433 72741 98.0 Intronic 2b   182263784 182320092
Dog 44082 45048 76.3 Intronic 966 36   24050981 24051947
Mouse 49275 49911 73.0 Intronic 636 2   75515401 75516037
Rat 48247 48892 72.3 Intronic 645 3   58405049 58405694
3 81.6 746.50 94.04
Human 63951 64978 – Intronic 1027 2   177856225 177857252
Chimpanzee 16433 72741 98.0 Intronic 2b   182263784 182320092
Dog 63914 64953 78.0 Intronic 1039 36   24070813 24071852
Mouse 69040 69553 74.9 Intronic 513 2   75535166 75535679
Rat 68447 68854 75.5 Intronic 407 3   58425249 58425656
4 82.8 962.25 98.86
Human 95699 97201 – Intronic 1502 2   177887973 177889475
Chimpanzee 93603 105622 98.3 Intronic 2b   182340954 182352973
Dog 94052 95563 80.9 Intronic 1511 36   24100951 24102462
Mouse 99967 100384 76.4 Intronic 417 2   75566093 75566510
Rat 103210 103629 75.7 Intronic 419 3   58460012 58460431
5 82.8 418.75 89.74
Human 112361 112533 – Intronic 172 2   177904635 177904807
Chimpanzee 113121 117879 98.1 Intronic 2b   182360472 182365230
Dog 105905 106887 82.1 Intronic 517 36   24112804 24113786
Mouse 115077 115617 74.8 Intronic 540 2   75581203 75581743
Rat 119448 119894 76.1 Intronic 446 3   58476250 58476696
(B)
1 78 491 86.58
Human 75272 75516 – Intergenic 244 4 + 103675774 103675545
Rat 190119 189890 77 Intergenic 229 2   233663290 233663525
Mouse 585736 585501 80 Intergenic 235 3   135287512 135286504
Dog 52140 53148 78 Intergenic 1008 32 + 26791395 26841008
Chimpanzee 67709 117322 98 Intergenic 49613 4 + 105654198 105654198
2 80 319 84.82
Human 93740 94016 – Intergenic 276 4 + 103659473 103659195
Rat 173818 173540 79 Intergenic 278 2   233651850 233652129
Mouse 574340 574061 78 Intergenic 279 3   135307030 135306630
Dog 72266 72666 81 Intergenic 400 32 + 26791395 26841008
Chimpanzee 67709 117322 98 Intergenic 49613 4 + 105654198 105654198
3 74 469 81.92
Human 148427 148852 – Intergenic 425 4 + 103626900 103626486
Rat 141245 140831 73 Intergenic 414 2   233620618 233620924
Mouse 543135 542829 73 Intergenic 306 3   135342413 135341726
Dog 107362 108049 76 Intergenic 687 32 + 26841253 26877988
Chimpanzee 117567 154302 99 Intergenic 36735 4 + 105654198 105654198
Chr¼chromosome; CNS¼conserved non-coding sequences.
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sthe ARE. Inflammation may also cause release of NF-kb1 from IkB
and stimulate NF-kb1 nuclear translocation to modulate transcrip-
tional response through the NF-kb1 response element, NF-kb-RE,
along with cofactors of NF-kb1. Several members of the MAPK
family may act in concert with Nrf2 and Nfkb1 with multiple
interactions between the members of the putative complex to elicit
the chemopreventive and pharmacotoxicological events in inflam-
mation and carcinogenesis.
Table 4 Canonical first-generation regulatory network members representing putative crosstalk between Nrf2 (Nfe2l2) and Nfkb1 in inflammation-
associated carcinogenesis
a
Sr.
no.
GenBank
accession no. Gene name
Gene
symbol
Papaiahgari
lung injury
and
inflammation
SFN+EGCG
Nrf2-
dependent
genes
BHA Nrf2-
dependent
genes
Tunicamycin
Nrf2-
dependent
genes
Faden
supra-
spinal
tracts
1 NM_172154 Ligand-dependent nuclear receptor corepressor Lcor –  3.25 – – –
2 NM_010756 v-maf musculoaponeurotic fibrosarcoma oncogene
family, protein G (avian)
Mafg – – 2.45 – –
3 NM_008927 Mitogen-activated protein kinase kinase 1 Map2k1  2.7  4.12 2.28 – 1.59
4 NM_023138 Mitogen-activated protein kinase kinase 2 Map2k2 – – 2.75 1.15 1.1
5 NM_009157 Mitogen-activated protein kinase kinase 4 Map2k4  1.55  3.31 –  1.68 –
6 NM_011840 Mitogen-activated protein kinase kinase 5 Map2k5  1.56 –  1.45 – 1.59
7 NM_011943 Mitogen-activated protein kinase kinase 6 Map2k6 –  3.98 – – 1.19
8 NM_011944 Mitogen-activated protein kinase kinase 7 Map2k7  1.32 –  0.37  0.16 –
9 NM_011945 Mitogen-activated protein kinase kinase kinase 1 Map3k1 – –  0.28  0.18 1.11
10 NM_011946 Mitogen-activated protein kinase kinase kinase 2 Map3k2 –  5.02 – 2.25 –
11 NM_011947 Mitogen-activated protein kinase kinase kinase 3 Map3k3  2.08 – – – –
12 NM_011948 Mitogen-activated protein kinase kinase kinase 4 Map3k4  1.87  3.52  1.98 1.51 –
13 NM_008580 Mitogen-activated protein kinase kinase kinase 5 Map3k5  1.71 – – –
14 NM_016693 Mitogen-activated protein kinase kinase kinase 6 Map3k6 1.58  5.25 3.25 – –
15 NM_172688 Mitogen-activated protein kinase kinase kinase 7 Map3k7 1.51  3.07 2.52 3.29 –
16 NM_025609 Mitogen-activated protein kinase kinase kinase
7-interacting protein 1
Map3k7ip1 –  3.93 –  1.91 –
17 NM_138667 Mitogen-activated protein kinase kinase kinase
7-interacting protein 2
Map3k7ip2  1.56 –– – –
18 NM_007746 Mitogen-activated protein kinase kinase kinase 8 Map3k8  2.04 –  0.58 2.76 1.55
19 NM_177395 Mitogen-activated protein kinase kinase kinase 9 Map3k9 –  6.48 3.06 4.77 –
20 NM_009582 Mitogen-activated protein kinase kinase kinase 12 Map3k12  7.07  3.51 –– –
21 NM_016896 Mitogen-activated protein kinase kinase kinase 14 Map3k14 1.38 – 2.12 1.51 –
22 NM_008279 Mitogen-activated protein kinase kinase kinase kinase 1 Map4k1 –  3.35 – – 1.4
23 NM_009006 Mitogen-activated protein kinase kinase kinase kinase 2 Map4k2  6.72 2.35  1.35 –
24 NM_001081357 Mitogen-activated protein kinase kinase kinase kinase 3 Map4k3  1.73 – – –
25 NM_008696 Mitogen-activated protein kinase kinase kinase kinase 4 Map4k4  1.58  3.54 2.46 –  0.74
26 NM_201519 Mitogen-activated protein kinase kinase kinase kinase 5 Map4k5  2.45  3.28 3.94  2.52 –
27 NM_031248 Mitogen-activated protein-binding protein-interacting protein Mapbpip 2.29 – – –
28 NM_001038663 Mitogen-activated protein kinase 1 Mapk1 – – – 1.08 1.51
29 NM_011952 Mitogen-activated protein kinase 3 Mapk3 (ERK1)  1.4  7.48 – – 1.09
30 NM_172632 Mitogen-activated protein kinase 4 Mapk4 –  3.51 – – 1.11
31 NM_015806 Mitogen-activated protein kinase 6 Mapk6 –  3.53 2.11 1.76 1.07
32 NM_011841 Mitogen-activated protein kinase 7 Mapk7  16.44 – – –  0.99
33 NM_016700 Mitogen-activated protein kinase 8 Mapk8 – – 10.39 12.43 1.21
34 NM_011162 Mitogen-activated protein kinase 8-interacting protein 1 Mapk8ip1 2.22  10.62 – –  0.84
35 NM_016961 Mitogen-activated protein kinase 9 Mapk9  1.88  4.77 1.68 2.33 1.4
36 NM_009158 Mitogen-activated protein kinase 10 Mapk10 1.47 – 2.25 – 1.29
37 NM_011161 Mitogen-activated protein kinase 11 Mapk11 –  10.9 1.78 2.32 –
38 NM_013871 Mitogen-activated protein kinase 12 Mapk12 – –  0.24 –  0.88
39 NM_011950 Mitogen-activated protein kinase 13 Mapk13 1.44 – –  0.21 –
40 NM_011951 Mitogen-activated protein kinase 14 Mapk14  1.62 – 1.14  0.46 1.38
41 NM_145527 Mitogen-activated protein kinase-activating death domain Mapkadd(Madd) – 1.03
42 NM_177345 Mitogen-activated protein kinase-associated protein 1 Mapkap1  1.62  6.56  0.34 – –
43 NM_008551 Mitogen-activated protein kinase-activated protein kinase 2 Mapkapk2 – – – 4.31 1.34
44 NM_178907 Mitogen-activated protein kinase-activated protein kinase 3 Mapkapk3 –  3.39 – 2.38 1.19
45 NM_010765 Mitogen-activated protein kinase-activated protein kinase 5 Mapkapk5 –  4.58  0.42  0.47 –
46 NM_011941 Mitogen-activated protein kinase binding protein 1 Mapkbp1 1.42 – – – –
47 NM_010881 Nuclear receptor coactivator 1 Ncoa1 –  3.55 – – –
48 NM_008679 Nuclear receptor coactivator 3 Ncoa3 – –  0.12 – –
49 NM_144892 Nuclear receptor coactivator 5 Ncoa5 – – – 14.65 –
50 NM_172495 Nuclear receptor coactivator 7 Ncoa7 –  4.46 – – –
51 NM_011308 Nuclear receptor corepressor 1 Ncor1 –  5.37 3.39 – –
52 NM_008689 Nuclear factor of kappa light chain gene enhancer in
B-cells 1, p105
Nfkb1  1.52 – – – 1.21
53 NM_019408 Nuclear factor of kappa light polypeptide gene enhancer
in B cells 2, p49/p100
Nfkb2  2.56 – – – –
54 NM_010907 Nuclear factor of kappa light-chain gene enhancer
in B-cell inhibitor, alpha
Nfkbia – – – –  0.77
55 NM_030612 Nuclear factor of kappa light polypeptide gene enhancer
in B cell inhibitor, zeta
Nfkbiz – – – 2.67 –
56 NM_028024 NFKB inhibitor-interacting Ras-like protein 2 Nkiras2  1.33 – – –  0.94
57 NM_010902 Nuclear factor, erythroid-derived 2, like 2 Nrf2 1.54 – – – 1.26
58 NM_173440 Nuclear receptor-interacting protein 1 Nrip1 – – 2.63 2.87 –
59 NM_020005 P300/CBP-associated factor P/caf – – – 2.33 –
BHA¼butylated hydroxyanisole; EGCG¼epigallocatechin-3-gallate; ER¼endoplasmic reticulum; SFN¼sulphoraphane.
aFold-change values are listed.
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Karin and Greten (2005) succinctly noted that carcinogenesis may
be divided into three mechanistic phases: initiation (which
involves stable genomic alterations), promotion (which involves
the proliferation of genetically altered cells) and progression
(which involves an increase in the size of the tumour, the
spreading of the tumour and the acquisition of additional genetic
changes). In 1863, Rudolf Virchow observed leukocytes in
neoplastic tissues and suggested (Balkwill and Mantovani, 2001)
that the ‘lymphoreticular infiltrate’ reflected the origin of cancer at
sites of chronic inflammation. Besides, persistent and recurrent
episodes of inflammation (McCulloch et al, 2006), mediated by
aberrant activation of innate and acquired immunity, characterise
a wide spectrum of idiopathic and infectious chronic inflammatory
disorders. In response to tissue injury (Coussens and Werb, 2002),
a multifactorial network of chemical signals initiate and maintain a
host response designed to ‘heal’ the afflicted tissue involving
activation and directed migration of leukocytes (neutrophils,
monocytes and eosinophils) from the venous system to sites of
damage, and tissue mast cells also play a significant role.
Interestingly, inflammation and innate immunity most commonly
exert pro-tumorigenic effects (Karin and Greten, 2005) mediated
through different types of leukocytes, including normal tissue
macrophages, tumour-associated macrophages, dendritic cells,
neutrophils, mast cells and T cells, which are recruited to the
tumour microenvironment through interactions with local stromal
cells and malignant cells. These leukocytes produce cytokines, and
growth and angiogenic factors, as well as matrix-degrading
proteases (such as the matrix metalloproteinases MMP1, MMP3
and MMP9) and their inhibitors, which allow tumour cells to
proliferate, invade and metastasise (Karin and Greten, 2005).
Although the causal relationship between inflammation, innate
immunity and cancer is more widely accepted, many of the
molecular and cellular mechanisms mediating this relationship
remain unresolved (Coussens and Werb, 2002). Many studies have
implicated Nrf2 (Nfe2l2) in cancer (Ramos-Gomez et al, 2001;
Katsuoka et al, 2005; Sporn and Liby, 2005; Nair et al, 2007a;
Pearson et al, 2008) or inflammation-associated diseases such as
colitis (Khor et al, 2006; Osburn et al, 2007), and Parkinson’s
disease (Clements et al, 2006), and NF-kB in inflammation
(Muller-Ladner et al, 2002; Profita et al, 2008; Puthia et al, 2008)
and cancer (Xu et al, 2005; Cilloni et al, 2006; Sun and Zhang, 2007;
McDonnell et al, 2008). Indeed, the identification of combinatorial,
or synergistic, transcription factors and the elucidation of
relationships among them are of great importance for under-
standing transcriptional regulation as well as transcription factor
networks (Hu et al, 2007). However, despite a growing recognition
of the important role(s) played by these two pivotal transcription
factors, the regulatory potential for crosstalk between these two
important transcription factors in inflammation and carcinogen-
esis has not been explored.
The perusal of several microarray data sets from public
repositories such as Oncomine, GEO, PEPR, as well as data sets
from the Kong Laboratory, facilitated the identification of 13 data
sets (Table 1) presenting distinct signatures of inflammation/
injury or carcinogenesis that served as our literature pre-screen for
concerted modulation of Nrf2 and Nfkb1 genes. The comparative
analyses of TFBS in these two gene promoters revealed that many
matrix families were conserved between human NRF2 and NFKB1
promoters, and between murine Nrf2 and Nfkb1 promoter regions
(Figure 1 and Table 2). Furthermore, as elucidated in Table 2,
several functionally important matrix families were also found to
be common across human and murine species, including activator
protein 4, E2F-myc activator/cell cycle regulators (V$E2FF), E-box-
binding factors, basic and erythroid krueppel-like factors, p53
tumour suppressor and RXR heterodimer-binding sites (V$RXRF),
among others. The identification of V$E2FF is significant because
disruption of retinoblastoma protein, a key controller of E2F
activity and G1/S transition in the cell cycle, can alter the growth-
inhibitory potential of TGF-b in the inflammatory milieu of
chronic liver disease and contribute to cancer development
(Sheahan et al, 2007). Inflammatory conditions can enhance the
genotoxic effects of carcinogenic polycyclic aromatic hydro-
carbons such as benzo[a]pyrene (BaP) through the upregulation
of CYP1B1 expression associated with increased phosphorylation
of p53 tumour suppressor at Ser-15 residue, enhanced accumu-
lation of cells in the S-phase of the cell cycle and potentiation of
BaP-induced apoptosis (Umannova et al, 2008). Thus, the presence
of conserved p53 TFBS in Nrf2/Nfkb1 promoters may point to a
critical role for inflammation in the etiopathogenesis of cancer and
underscore the relevance of crosstalk between these two transcrip-
tion factors. The identification of V$RXRF is important as RXR
physically interacts with peroxisome proliferator-activated recep-
tor (PPAR-a), a major player in lipid metabolism and inflamma-
tion, and PPAR-a agonists such as fenofibrate inhibit NF-kB
DNA-binding activity (Xu et al, 2006). In addition, a conserved
TFBS for NF-kB itself (Table 2) was found to be present in murine
promoter regions of Nrf2 and Nfkb1, strengthening the potential
for crosstalk between these two transcription factors. Our multiple
sequence alignments (Figures 2A and B and Tables 3A and B)
enabled the study of conserved biological features for each gene
across five mammalian species and the construction of a
phylogenetic tree (Figure 2C). Interestingly, several key biological
features were elicited on subjecting the top three conserved human
sequences of each gene to comparative promoter analyses
(Figure 2D and Table 2). Notably, autoimmune regulatory
element-binding factors (V$AIRE) and PPAR (or V$PERO) were
conserved in these promoters. Recently, a cyclopentenonic
prostaglandin 15-deoxy-delta(12,14)-prostaglandin J(2) has been
shown to inhibit TNF-related apoptosis-inducing ligand mRNA
expression by downregulating the activity of its promoter in T
lymphocytes, with NF-kB being identified as a direct target of this
prostanoid that is also regulated by the activation of PPAR-g
(Fionda et al, 2007). The identification of PPAR in the promoter
regions of Nrf2 and Nfkb1 in this study, thus, reinforces the
significance of these transcription factors and provides a possible
mechanistic pathway for crosstalk in inflammation and cancer.
Interestingly, a recent study (Kim et al, 2008) has reported that
treatment of human brain astrocytes with double-stranded RNA
induced interferon regulatory factor 3 (IRF3) phosphorylation and
nuclear translocation followed by activation of STAT1 along with a
concomitant activation of NF-kB and MAPK cascade members
(p38, JNK and ERK). In this study, we identified interferon
regulatory factors (IRFF) and STAT as being conserved in Nrf2 and
Nfkb1 promoters, as well as MAPK members in our regulatory
network (Figure 3A), which agrees with the mechanistic evidence
from the brain astrocyte study. It has been observed (Tliba et al,
2006) that stimulation with pro-inflammatory cytokines of CD38,
known to be responsible for lung airway inflammation, rendered it
Figure 3 A canonical regulatory network for Nrf2–Nfkb1 interactions in inflammation-associated carcinogenesis. (A) A putative regulatory network for
Nrf2 (Nfe2l2) and Nfkb1 representing 59 nodes and 253 potential interactions implicating several members of the MAPK family; (B) literature network in
humans; (C) literature network in mice; (D) functional crosstalk in biological network of Nfe2l2, Nfkb1 and various members of the MAPK cascade; (E)
differential expression of MAPKs in cancer vs developmental or non-cancerous tissue/cell lines (GSM116104–116106: bronchial smooth muscle cells;
GSM133871–133873: retinal pigment epithelial cell line; GSM156176–156178: skeletal muscle; GSM187371–187373: untreated LNCaP cells;
GSM211446–211448: normal adrenal gland; GSM286756–286758: untreated MCF7 cells; GSM74875–74880: benign prostate tissue; GSM74881–
74887: clinically localised primary prostate cancer; GSM74888–74893: metastatic prostate cancer).
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dexamethasone or budesonide, by inhibiting steroid-induced
glucocorticoid-responsive element (GRE)-dependent gene tran-
scription. We also identified conserved GRE in the Nrf2/Nfkb1
promoters that further validated our results as biologically
relevant. In addition, cell cycle regulators, heat-shock factors and
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genes, thus, underscoring the biological relevance, and the
intrinsic complexity, of Nrf2/Nfkb1 crosstalk from a functional
standpoint.
Further, we streamlined our study to five data sets (Table 4),
which were representative of the most distinct inflammation/injury
and cancer signatures of interest and constructed a canonical first-
generation regulatory network (Figure 3A) for Nrf2 (Nfe2l2) and
Nfkb1, representing 59 nodes and 253 potential interactions. We
generated functionally relevant PubGene literature networks in
human (Figure 3B) and mouse (Figure 3C), using the Ingenuity
Knowledge Base (Figure 3D), thus delineating gene signatures that
validated the biological role(s), and potential for crosstalk, of the
genes elucidated in this in silico study. We also assessed the
expression of MAPKs in several randomly picked, unrelated
microarray data sets of cancerous and non-cancerous origin and
showed that various MAPKs are differentially expressed in cancer
vs developmental or non-cancerous tissue/cell lines (Figure 3E).
Our future study includes the expansion of our study objectives to
generate more detailed second-generation or third-generation
regulatory networks for Nrf2 and Nfkb1 as more functional data
emerge on these gene targets of interest and their interactions with
coactivator/corepressor modules that associate with them. Inter-
estingly, as shown in our current first-generation network
(Figure 3A), several MAPKs play a central role in mediating the
transcriptional effects of Nrf2 and Nfkb1. This is, indeed, in
consonance with the known role of MAPKs in potentiating Nrf2-
mediated ARE activation (Yu et al, 2000; Shen et al, 2004; Yuan
et al, 2006) and their role in modulating NF-kB (Murakami et al,
2007; de Sousa et al, 2007), thus, further underscoring the biological
applicability of our results. Finally, we present a gestalt pictorial
overview (Figure 4) of our current knowledge of concerted
modulation of Nrf2 and Nfkb1 based on the data from this study
and our extensive experience in cancer chemoprevention.
The results from our current in silico study may strengthen the
possibility that scientists could, in the future, consider pursuing
Nrf2, Nfkb1 and MAPKs as potential targets in early drug
discovery screens for the management of inflammation and
cancer. In contemporary times, systems biology has interfaced
with the drug discovery process to enable high-throughput
screening of multiple drug targets and target-based leads. Indeed,
a combination of high-throughput screening, kinase-specific
libraries and structure-based drug design has facilitated the
discovery of selective kinase inhibitors (Manning and Davis,
2003). Needless to add, the benefits of applying molecular profiling
to drug discovery and development include much lower failure
Figure 4 A putative model for Nrf2-–Nfkb1 interactions in inflammation and carcinogenesis. Chemical signals generated by dietary chemopreventive
agents or toxicants, or inflammatory signals, may cause Nrf2 nuclear translocation that sets in motion a dynamic machinery of coactivators and corepressors
that may form a multimolecular complex with Nrf2 for modulating transcriptional response through the antioxidant response element, ARE. Inflammation
may also cause release of NF-kB from IkB and stimulate NF-kB nuclear translocation to modulate transcriptional response through the NF-kB response
element, NF-kB-RE, along with the cofactors of NF-kB. Several members of the MAPK family may act in concert with Nrf2 and Nfkb1 with multiple
interactions between the members of the putative complex to elicit the chemopreventive and pharmacotoxicological events in inflammation and
carcinogenesis.
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srates at all stages of the drug development pipeline, faster
progression from discovery through to clinical trials and more
successful therapies for patient subgroups (Stoughton and Friend,
2005). Thus, the development of specific inhibitors that might
regulate the specific crosstalk between the two central pleiotropic
transcription factors Nrf2 and Nfkb1, and with the associated
family of kinases, may be one of many strategies that might aid in
the drug discovery process. Taken together, our study provides a
canonical framework to understand the regulatory potential for
concerted modulation of Nrf2 and Nfkb1 in inflammation and
cancer. Further studies addressing this question with specific
emphasis on cofactor modules binding to these transcription
factors and coregulation with upstream signalling molecules in the
MAPK cascade will enable a better appreciation of the emerging
key role(s) of, and the crosstalk between, these two transcription
factors in inflammation and carcinogenesis.
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